Charles River Laboratories to Acquire Cognate BioServices to Create a Premier Scientific Partner for Cell and Gene Therapy Development
Go back to Charles River Laboratories to Acquire Cognate BioServices to Create a Premier Scientific Partner for Cell and Gene Therapy Development| CHARLES RIVER LABORATORIE (NYSE: CRL) | Delayed: 282.91 +9.50 (3.47%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $273.41 | 52 Week High | $89.18 | |||
| Open | $280.11 | 52 Week Low | $65.70 | |||
| Day High | $282.91 | P/E | 131.59 | |||
| Day Low | $274.40 | EPS | $2.15 | |||
| Volume | 167,810 | |||||
